Tag: Ocugen

Biopharmaceutical firm Ocugen is transitioning from clinical development to the regulatory phase, with its lead gene therapy candidate approaching a ...

Positive results from a mid-stage clinical study have prompted several Wall Street research firms to revise their outlook on Ocugen, ...

A recent clinical trial update from Ocugen has prompted a significant reassessment of the company's prospects among Wall Street analysts. ...

In a counterintuitive market reaction, Ocugen's stock price declined significantly following the announcement of encouraging 12-month data from its Phase ...

In a surprising market reaction, shares of biotechnology firm Ocugen experienced a significant sell-off this week, even as the company ...

Ocugen, Inc. has bolstered its balance sheet without initiating a new formal funding round. The capital infusion came via the ...

The investment thesis for biopharmaceutical company Ocugen is gaining notable support on Wall Street. In a significant endorsement, the firm ...

The biotech firm Ocugen has staged a remarkable recovery in recent months, capturing renewed attention from institutional investors. This resurgence ...

A new research report from Canaccord Genuity triggered a significant rally for Ocugen Inc. on Tuesday. The firm initiated coverage ...

The stock of biotechnology firm Ocugen has experienced a significant rally, propelled by a combination of promising clinical developments for ...